Iconovo
Market Cap
kr454.0m
Last Updated
2019/12/06 21:43 UTC
Data Sources
Company Financials +
Executive Summary
Iconovo AB (publ) develops and licenses inhalation devices in Sweden.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with excellent balance sheet.
Share Price & News
How has Iconovo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICO has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-4.1%
ICO
-0.3%
SE Medical Equipment
1.0%
SE Market
1 Year Return
97.6%
ICO
39.1%
SE Medical Equipment
22.5%
SE Market
Return vs Industry: ICO exceeded the Swedish Medical Equipment industry which returned 39.1% over the past year.
Return vs Market: ICO exceeded the Swedish Market which returned 22.5% over the past year.
Shareholder returns
| ICO | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.1% | -0.3% | 1.0% |
| 30 Day | 7.8% | -1.0% | 0.7% |
| 90 Day | 17.8% | 9.0% | 8.4% |
| 1 Year | 97.6%97.6% | 40.7%39.1% | 27.6%22.5% |
| 3 Year | n/a | 68.2%48.6% | 34.2%13.7% |
| 5 Year | n/a | 71.1%44.1% | 61.8%27.0% |
Price Volatility Vs. Market
How volatile is Iconovo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What Kind Of Shareholder Appears On The Iconovo AB (publ)'s (STO:ICO) Shareholder Register?1 month ago | Simply Wall St
Does Iconovo's (STO:ICO) Share Price Gain of 44% Match Its Business Performance?2 months ago | Simply Wall St
Iconovo (STO:ICO) Is In A Good Position To Deliver On Growth PlansValuation
Is Iconovo undervalued compared to its fair value and its price relative to the market?
7.46x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ICO (SEK66.2) is trading above our estimate of fair value (SEK0.3)
Significantly Below Fair Value: ICO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ICO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: ICO is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICO is overvalued based on its PB Ratio (7.5x) compared to the SE Medical Equipment industry average (4.3x).
Next Steps
Future Growth
How is Iconovo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
129.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: ICO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICO's is expected to become profitable in the next 3 years.
Revenue vs Market: ICO's revenue (39.2% per year) is forecast to grow faster than the Swedish market (4.5% per year).
High Growth Revenue: ICO's revenue (39.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICO's Return on Equity is forecast to be low in 3 years time (11.1%).
Next Steps
Past Performance
How has Iconovo performed over the past 5 years?
-1096.3%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ICO is currently unprofitable.
Growing Profit Margin: ICO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ICO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ICO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: ICO has a negative Return on Equity (-6.31%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Iconovo's financial position?
Financial Position Analysis
Short Term Liabilities: ICO's short term assets (SEK47.5M) exceed its short term liabilities (SEK4.3M).
Long Term Liabilities: ICO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ICO is debt free.
Reducing Debt: ICO had no debt 5 years ago.
Balance Sheet
Inventory Level: ICO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ICO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ICO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Iconovo's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ICO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ICO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
What is the CEO of Iconovo's salary, the management and board of directors tenure and is there insider trading?
2.9yrs
Average board tenure
CEO
Orest Lastow (55yo)
0yrs
Tenure
Dr. Orest Lastow serves as Chief Executive Officer and Head of R&D at Iconovo AB (publ). He Founded it in 2013.
Board Age and Tenure
2.9yrs
Average Tenure
54yo
Average Age
Experienced Board: ICO's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: ICO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Operating Officer Vice President of Operations |
| Shares | 54.6 |
| Max Price | kr54.60 |
| Entity | Individual |
| Shares | 500 |
| Max Price | kr40.00 |
| Entity | Individual |
| Shares | 300 |
| Max Price | kr42.00 |
| Entity | Individual |
| Shares | 500 |
| Max Price | kr43.02 |
| Entity | Individual |
| Shares | 750 |
| Max Price | kr42.47 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 5,000 |
| Max Price | kr32.92 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Anna Gallon (48yo)
Chief Financial Officer
- Tenure: 0.9yrs
Orest Lastow (55yo)
CEO, Head of R&D and Director
- Tenure: 0yrs
Mikael Arinder
Vice President of Operations
- Tenure: 0yrs
Carl Forslund
Head of Industrial Design
- Tenure: 0yrs
Board Members
Mats Johansson (58yo)
Chairman of the Board
- Tenure: 6.9yrs
Kjell Larsson
Member of Scientific Advisory Board
- Tenure: 0yrs
Leif Hansen (53yo)
Director
- Tenure: 1.9yrs
Lennart Holm (59yo)
Member of Business Advisory Board
- Tenure: 0yrs
Rikard Roos (45yo)
Member of Business Advisory Board
- Tenure: 0yrs
Orest Lastow (55yo)
CEO, Head of R&D and Director
- Tenure: 0yrs
Berndt Axelsson (60yo)
Director
- Tenure: 6.9yrs
Björn Andersson
Member of Business Advisory Board
- Tenure: 0yrs
Maria Bech (51yo)
Independent Director
- Tenure: 1.9yrs
Sven Totté (50yo)
Director
- Tenure: 2.9yrs
Company Information
Iconovo AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Iconovo AB (publ)
- Ticker: ICO
- Exchange: OM
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr453.992m
- Shares outstanding: 6.78m
- Website: https://www.iconovo.se
Location
- Iconovo AB (publ)
- Medicon Village
- Scheelevägen 2
- Lund
- Skåne County
- 223 81
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ICO | OM (OMX Nordic Exchange Stockholm) | Yes | Common Shares | SE | SEK | Apr 2018 |
Biography
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a reservoir-based dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a unit dose disposable dr ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/06 21:43 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.